Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $205.00 target price on the biotechnology company's stock. Needham & Company LLC's price objective suggests a potential upside of 64.83% from the stock's current price.

Several other brokerages have also recently weighed in on SRPT. Evercore ISI upgraded Sarepta Therapeutics from an "in-line" rating to an "outperform" rating and reduced their price target for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Royal Bank of Canada lifted their target price on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the company an "outperform" rating in a report on Friday, October 4th. Barclays decreased their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research note on Thursday, August 8th. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Finally, William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $183.89.

Sarepta Therapeutics Stock Down 0.1 %

Shares of SRPT stock traded down $0.14 on Monday, hitting $124.37. The stock had a trading volume of 414,706 shares, compared to its average volume of 1,265,014. The business has a 50 day moving average price of $129.87 and a 200 day moving average price of $132.47. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The company has a market cap of $11.76 billion, a PE ratio of 1,130.64 and a beta of 0.82. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.27) EPS. Research analysts anticipate that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Michael Andrew Chambers acquired 37,038 shares of the firm's stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in SRPT. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company's stock valued at $850,139,000 after acquiring an additional 243,180 shares in the last quarter. Capital International Investors lifted its position in Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company's stock valued at $623,676,000 after purchasing an additional 76,032 shares during the period. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company's stock worth $398,025,000 after acquiring an additional 217,810 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after acquiring an additional 37,940 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.